Bluebird Ventures
755 Page Mill Road, Suite A200, Palo Alto, CA, 94304, United States
Overview
Investment portfolio
| NAME | DATE | SIZE | |
|---|---|---|---|
Leyden Labs | Jan 2025Participated | $70 MOther Equity | |
Foresight Diagnostics | Jul 2024Participated | $33 MSeries B | |
Procyrion | Feb 2024Participated | $58 MSeries E | |
Foresight Diagnostics | Apr 2023Participated | $59 MSeries B | |
Kriya Therapeutics | May 2022Participated | $270 MSeries C | |
Leyden Labs | Jan 2022Participated | $140 MSeries B | |
Kriya Therapeutics | Jul 2021Participated | $100 MSeries B | |
Nutcracker Therapeutics | Sep 2020Participated | $60 MSeries B | |
Kriya Therapeutics | May 2020Participated | $81 MSeries A | |
Epirium Bio | Dec 2019Participated | $85 MSeries A | |
Procyrion | Jul 2019Led | $30 MSeries D | |
Leyden Labs | Jan 2025Participated | $70 MOther Equity | |
Foresight Diagnostics | Jul 2024Participated | $33 MSeries B | |
Procyrion | Feb 2024Participated | $58 MSeries E | |
Foresight Diagnostics | Apr 2023Participated | $59 MSeries B | |
Kriya Therapeutics | May 2022Participated | $270 MSeries C | |
Leyden Labs | Jan 2022Participated | $140 MSeries B | |
Kriya Therapeutics | Jul 2021Participated | $100 MSeries B | |
Nutcracker Therapeutics | Sep 2020Participated | $60 MSeries B | |
Kriya Therapeutics | May 2020Participated | $81 MSeries A | |
Epirium Bio | Dec 2019Participated | $85 MSeries A | |
Procyrion | Jul 2019Led | $30 MSeries D |
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Series A | 0 | 2 |
| Series B | 0 | 5 |
| Series C+ | 1 | 2 |
| Other Equity | 0 | 1 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Jul '19 | 1 |
| Aug '19 | 0 |
| Sep '19 | 0 |
| Oct '19 | 0 |
| Nov '19 | 0 |
| Dec '19 | 1 |
| Jan '20 | 0 |
| Feb '20 | 0 |
| Mar '20 | 0 |
| Apr '20 | 0 |
| May '20 | 1 |
| Jun '20 | 0 |
| Jul '20 | 0 |
| Aug '20 | 0 |
| Sep '20 | 1 |
| Oct '20 | 0 |
| Nov '20 | 0 |
| Dec '20 | 0 |
| Jan '21 | 0 |
| Feb '21 | 0 |
| Mar '21 | 0 |
| Apr '21 | 0 |
| May '21 | 0 |
| Jun '21 | 0 |
| Jul '21 | 1 |
| Aug '21 | 0 |
| Sep '21 | 0 |
| Oct '21 | 0 |
| Nov '21 | 0 |
| Dec '21 | 0 |
| Jan '22 | 1 |
| Feb '22 | 0 |
| Mar '22 | 0 |
| Apr '22 | 0 |
| May '22 | 1 |
| Jun '22 | 0 |
| Jul '22 | 0 |
| Aug '22 | 0 |
| Sep '22 | 0 |
| Oct '22 | 0 |
| Nov '22 | 0 |
| Dec '22 | 0 |
| Jan '23 | 0 |
| Feb '23 | 0 |
| Mar '23 | 0 |
| Apr '23 | 1 |
| May '23 | 0 |
| Jun '23 | 0 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 0 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 0 |
| Jan '24 | 0 |
| Feb '24 | 1 |
| Mar '24 | 0 |
| Apr '24 | 0 |
| May '24 | 0 |
| Jun '24 | 0 |
| Jul '24 | 1 |
| Aug '24 | 0 |
| Sep '24 | 0 |
| Oct '24 | 0 |
| Nov '24 | 0 |
| Dec '24 | 0 |
| Jan '25 | 1 |
| Feb '25 | 0 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 0 |
| Nov '25 | 0 |
| Dec '25 | 0 |
| Jan '26 | 0 |
| Feb '26 | 0 |
| Mar '26 | 0 |
| Apr '26 | 0 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 0 |
| Aug '26 | 0 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 11 |
| Space & Frontier Tech | 3 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 0 |
| $5M-$10M | 0 |
| $10M-$25M | 0 |
| $25M-$50M | 2 |
| $50M-$100M | 6 |
| $100M-$250M | 2 |
| $250M-$500M | 1 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 2 of 2 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| United States | 9 |
| Europe | 2 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| Foresite Capital | 5 |
| Dexcel Pharma | 3 |
| Narya Capital | 3 |
| QVT | 3 |
| Transhuman Capital | 3 |
| Agent Capital | 2 |
| Amplo | 2 |
| ARCH Venture Partners | 2 |
| Byers Capital | 2 |
| CAM Capital | 2 |
| Casdin Capital | 2 |
| Civilization Ventures | 2 |
| F-Prime Capital | 2 |
| Fannin Partners | 2 |
| Google Ventures | 2 |
| Invus | 2 |
| Patient Square Capital | 2 |
| Pear VC | 2 |
| SoftBank | 2 |
| Stanford University | 2 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 1 | 9% |
| Participating | 10 | 91% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 1 | 100% |
| Co-led | 0 | 0% |
Team
Founder and Managing Director